IP Library Granted Patent US 11,932,883
Granted Patent B2
US 11,932,883 · App. 17/319,849 · Granted Mar 19, 2024

CRISPR-associated (Cas) protein

Inventors: Matthew Merrill Carter (San Diego, CA); Paul Daniel Donohoue (San Diego, CA)
Assignee: Locanabio, Inc.
C12N9/22C12N15/11C12N15/111C12N15/1136C12N15/85C12N2310/20C12N2800/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,932,883
App. No.
17/319,849
Granted
Mar 19, 2024
Kind
B2
Abstract

A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.

Claims (12)

1. A Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) nucleoprotein complex, wherein the nucleoprotein complex comprises a Cas protein having at least 95 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 38; and

a cognate nucleic acid guide comprising a repeat sequence and a spacer sequence, wherein the repeat sequence and the spacer sequence do not naturally occur together, wherein the Cas protein and the cognate nucleic acid guide form the nucleoprotein complex, and wherein the nucleoprotein complex is capable of site-directed binding to a target nucleic acid sequence.

2. The Cas nucleoprotein complex of claim 1 , wherein the cognate nucleic acid guide comprises a crRNA.

3. The Cas nucleoprotein complex of claim 1 , wherein the Cas protein comprises an N- or C-terminal nuclear localization signal sequence (NLS).

4. The Cas nucleoprotein complex of claim 1 , wherein the cognate nucleic acid guide comprises a modified base analog.

5. The Cas nucleoprotein complex of claim 1 , wherein the sequence identity is calculated using a computer program with default parameters.

6. A eukaryotic cell comprising the Cas nucleoprotein complex of claim 1 .

7. The eukaryotic cell of claim 6 , further comprising one or more additional Cas nucleoprotein complexes.

8. The eukaryotic cell of claim 7 , wherein the eukaryotic cell is a human cell.

9. The Cas nucleoprotein complex of claim 1 , wherein the Cas protein is catalytically active.

10. The Cas nucleoprotein complex of claim 1 , wherein the Cas protein is catalytically inactive.

11. The Cas nucleoprotein complex of claim 1 , wherein the Cas protein comprises a fusion protein.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2021
From: CARTER, MATTHEW MERRILL; DONOHOUE, PAUL DANIEL
To: CARIBOU BIOSCIENCES, INC.
Reel/Frame 056933/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2021
From: CARIBOU BIOSCIENCES, INC.
To: LOCANA, INC.
Reel/Frame 056933/0729 →
CHANGE OF NAME Recorded Jul 21, 2021
From: LOCANA, INC.
To: LOCANABIO, INC.
Reel/Frame 056988/0005 →
Continuity (5)
Continuation 16693182 · Nov 22, 2019
Division 15937840 · Mar 27, 2018
Provisional Application 62477494 · Mar 28, 2017
Provisional Application 62629641 · Feb 12, 2018
Related Publication 20210269785A1 · Sep 2, 2021